← Back to Clinical Trials
Recruiting NCT06549829

The Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Hepatocellular Carcinoma

Trial Parameters

Condition Hepatocellular Carcinoma
Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age 70 Years
Start Date 2024-09-01
Completion 2025-12-31
Interventions
Nutritional optimization-led triple prehabilitation InterventionConventional triple prehabilitation Intervention

Brief Summary

The aim of this project is to investigate the effect of triple prehabilitation led by nutritional optimization in liver cancer patients' surgery. It improves the preoperative nutritional status of cancer patients, reduces the incidence of early postoperative complications, promotes postoperative recovery, and improves the quality of patients' survival. Patients were randomized into experimental and control groups based on exclusion and inclusion criteria. Nutritional interventions and exercise and psychological interventions for patients. Interventions will continue for two weeks prior to surgery. Routine clinical blood tests will be performed at the time of enrollment, on the first day before surgery and on the first, third and fifth days after surgery. Enrolled patients were followed up by telephone or outpatient clinic at 1,3,6 months postoperatively.

Eligibility Criteria

Inclusion Criteria: * Patients diagnosed with primary liver cancer. * Patients between the ages of 18 and 70. * Patients who are feasible for surgical treatment after clinical evaluation. ④Major organ function meets the following conditions: neutrophil count \>1.5\*109/L; platelet count \>100\* 109/L; hemoglobin \>90g/L; transaminase and creatinine \<twice the upper limit. Exclusion Criteria: * Patients with liver metastases or combined with other tumors. ②Patients with allergy to the ingredients of nutritional preparations. * Patients with severe malnutrition who cannot eat by mouth. ④Patients with hyperthyroidism, fistula, and combined digestive system diseases.

Related Trials